Fubotv earnings beat by $0.10, revenue topped estimates
GLEN ALLEN, VA—Genworth Holdings, Inc. recently executed a significant stock sale involving its subsidiary, Enact Holdings , Inc. (NASDAQ:ACT), a $5.3 billion market cap company with "GREAT" financial health according to InvestingPro. According to a regulatory filing, Genworth sold 533,538 shares of Enact Holdings’ common stock on February 28, 2025. The transaction was completed at a weighted average price of $33.5464 per share, amounting to a total value of approximately $17.9 million.
This transaction was conducted under a previously established Share Repurchase Agreement between the two companies, dated May 1, 2024. Following the sale, Genworth Holdings retains ownership of approximately 122.75 million shares, maintaining its position as a major stakeholder with about 81% of Enact’s outstanding common stock. The company, which boasts a robust 78% gross profit margin, appears undervalued according to InvestingPro’s Fair Value analysis. Discover detailed valuation metrics and 5 additional ProTips with an InvestingPro subscription.
The agreement governing this transaction can be reviewed in detail in Enact Holdings’ Form 10-Q for the quarterly period ended March 31, 2024, available on the SEC’s website.
In other recent news, Alchimp Group AG reported its Q4 2024 earnings, showing a mixed performance with an earnings per share (EPS) of $1.09, which exceeded the forecast of $1.04. However, the company’s revenue fell short at $301.77 million compared to the expected $309.37 million. The specialty chemicals segment was a significant contributor, accounting for 63% of sales, and the company achieved record sales of €554 million for the year. Despite the revenue miss, Alchimp’s EBITDA increased by 30% to €105.3 million, with a margin improvement to 19%. A proposed dividend increase of 50% to €1.8 per share was also announced. Looking forward, Alchimp Group AG has set a sales guidance of €580 million for 2025, representing 5% growth, and an EBITDA target of €113 million, a 7% increase. The company plans to invest approximately €100 million in capital expenditures, focusing on expanding its specialty chemicals segment. Additionally, Alchimp Group AG is exploring mergers and acquisitions opportunities in the U.S. to bolster its growth strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.